An efficient and robust synthetic procedure was developed primarily for the synthesis of a precursor compound; 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1, 2, 4]triazolo[4,3-a]pyrazine (11), from 2-chloropyrazine (7) through the chemical transformations such as hydrazine substitution, trifluoroacetyl group induction, cyclization and pyrazine ring reduction. A new series of urea derivatives 13a-e and thiourea derivatives 13f-j of compound 11 have been synthesized and the structures of all the compounds were confirmed using spectroscopic analyses such as IR, 1H NMR, 13C NMR, LC-MS and HRMS. The newly synthesized compounds were screened for their in vitro antimicrobial activity against five bacteria and two fungi, in which compounds 13d, 13i and 13j displayed potential activity against bacterial strains and 13a, 13d, 13g and 13j against fungal strains with the MIC values in the range of 6.25–25.0 µg/mL. An overall comparison of the activity results revealed that thiourea derivatives contain better activity than that of urea compounds. Molecular docking studies on poly (ADP-ribose) polymerase 15 (ARTD7, BAL3) demonstrated that all the synthesized compounds possess significant binding energies (-8.1 to -9.8 kcal/mol) with no adverse effect in the active site of protein.
14 September 2017 in Research on Chemical Intermediates
In the present study, a new series of (bis)ureas 11(a–f) and (bis)thioureas 13(a–f) of 3,3'-dimethoxy-[1,1'-biphenyl]-4,4'-diamine dihydrochloride (9) has been synthesized. This precursor intermediate 9 in high yields was preparedfrom the commercial starting material, 4,4'-dinitro-[1,1'-biphenyl]-3,3'-diol (7) by following the chemical transformations such as methylation of hydroxyl groups and reduction of nitro to an amine functionality. Antimicrobial and antioxidant activities of the synthesized compounds were evaluated to screen for their biological significance. Antimicrobial activity screening results against four bacteria and two fungi unveiled that a few compounds, 11 b/13b, 11e/13e, and 11d (MIC 3.125 − 6.25 µg/ml) against all the tested bacterial strains and compound 11d against Cladosporium species (MIC 3.125 µg/ml) having potential activity. Especially, (bis)urea compounds 11a, 11 b, and 11e, and (bis)thiourea compounds 13a, 13d, and 13f (MIC 3.125 µg/ml) are proved the comparable activity with standard, cefixime (MIC 3.125 µg/ml) against P. aeruginosa. On the other hand, a few compounds 11c/13c, 13d, and 11e/13e were found, by using DPPH and FRAP methods, to exhibit a good antioxidant activity (IC50 range 25.0–32.5 µg/ml). The synthesized compounds were docked well in the active site of an enzyme, DNA Gyrase A, and the predictions of in silico-ADME and pharmacokinetic parameters suggest that the compounds have good oral bioavailability. The results demonstrate that this class of compounds has an expedient scope to use as antibacterial and antioxidant agents upon further development.